Flora Growth Reports Rising Revenue

Flora says its on track for revenue guidance.

Flora Growth Corp. (NASDAQ: FLGC)  reported its financial results for the third quarter ending September 30, 2022, with revenue increasing 414% over last year to $10.8 million. Flora attributed some of the growth to the acquisitions of JustCBD and Vessel. Still, the company delivered a net loss of approximately $7.4 million versus last year’s net loss of $3.6 million.

On a positive note, Flora Growth said it remains on track to meet its 2022 revenue guidance of $35-45 million.

“The third quarter of 2022 was another exciting quarter for Flora as we continued to lay the foundation of our business for the long term,” said Luis Merchan, Chairman a CEO of Flora Growth. “During the quarter, we exported products to several new markets, including distribution of our Colombian-grown high-CBD dried cannabis flower to Switzerland and the Czech Republic, as well as CBD isolate to the United States. Our global distribution network, coupled with our high-quality Colombian flower and derivatives, leave Flora well positioned to capitalize on the evolving global cannabis landscape.”

Cash Burn

As of September 30, 2022, Flora Growth said it had roughly $5.9 million in cash, a big drop from the $37.6 million it had at the end of 2021. The company said the decrease was primarily due to cash paid for the acquisition of JustCBD, as well as higher operating expenses related to investments in headcount, sales and marketing, and one-time expenses associated with Cosechemos operations and the Flora Lab expansion.

Merchan went on to say, “Subsequent to the quarter, we signed a definitive agreement to acquire Franchise Global Health, a pharmaceutical and medical cannabis distributor with principal operations in Germany. This transformative deal would connect our Colombian commercial infrastructure and product portfolio to the German and EU cannabis markets, allowing Flora to significantly increase its international footprint.

On October 21, 2022, Flora and FGH entered into a deal for Flora to buy FGH in an all-stock deal. Flora will issue between 36,515,060 and 43,525,951 of its common shares for the acquisition.

“As we look ahead to the end of the year, we expect to finalize the transaction and solidify our presence in the European cannabis market. With our industry-leading production costs and expanding global footprint, we believe our business is well positioned to accelerate growth into 2023 and beyond.”

Debra Borchardt

Debra Borchardt is the Co-Founder, and Executive Editor of GMR. She has covered the cannabis industry for several years at Forbes, Seeking Alpha and TheStreet. Prior to becoming a financial journalist, Debra was a Vice President at Bear Stearns where she held a Series 7 and Registered Investment Advisor license. Debra has a Master's degree in Business Journalism from New York University.

Leave a Reply

Your email address will not be published. Required fields are marked *

Get the latest cannabis news delivered right to your inbox

The Morning Rise

Unpack the industry with the daily cannabis newsletter for business leaders.

 Sign up

About Us

The Green Market Report focuses on the financial news of the rapidly growing cannabis industry. Our target approach filters out the daily noise and does a deep dive into the financial, business and economic side of the cannabis industry. Our team is cultivating the industry’s critical news into one source and providing open source insights and data analysis


Recent Tweets

Get the latest cannabis news delivered right to your inbox

The Morning Rise

Unpack the industry with the daily cannabis newsletter for business leaders.